Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | MGLL | Q99685 | 3/20 | 0.49 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | ENPP2 | Q13822 | 3/20 | 0.45 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
| ▸ | SCD | O00767 | 1/20 | 0.42 |
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL411985 | 0.83 | ALDH1A1 (0.48) | TP53MAPTNPC1RAB9AALDH1A1 | |
| SCHEMBL20508280 | 0.83 | EPHX2 (0.47) | MAPTNPC1RAB9AALDH1A1SMN1; SMN2 | |
| SCHEMBL4823829 | 0.82 | POLB (0.54) | TP53MAPTNPC1RAB9AALDH1A1 | |
| SCHEMBL1530791 | 0.80 | MAPT (0.50) | TP53MAPTNPC1RAB9AALDH1A1 | |
| SCHEMBL19510960 | 0.80 | NPC1 (0.44) | TP53MAPTNPC1RAB9AALDH1A1 | |
| SCHEMBL3726907 | 0.80 | CXCR2 (0.41) | NPC1RAB9AALDH1A1SMN1; SMN2 | |
| SCHEMBL13035973 | 0.78 | CA12 (0.43) | ALDH1A1 | |
| SCHEMBL17653814 | 0.78 | MGLL (0.59) | TP53MAPTNPC1RAB9AALDH1A1 | |
| SCHEMBL591401 | 0.78 | MGLL (0.59) | TP53MAPTNPC1RAB9AALDH1A1 | |
| SCHEMBL5918956 | 0.77 | HDAC1 (0.41) | MAPTNPC1RAB9AALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4344702-B1 | PYRAZOLYL DERIVATIVES USEFUL AS ANTI-CANCER AGENTS | NOVARTIS AG (CH) | 2026-01-28 | — | — | EP | disclosed |
| US-20250325677-A1 | STAT6 DEGRADERS | GILEAD SCIENCES INC (US) | 2025-10-23 | — | — | US | disclosed |
| US-20250320206-A1 | STAT6 DEGRADERS | GILEAD SCIENCES INC (US) | 2025-10-16 | — | — | US | disclosed |
| US-20250320205-A1 | STAT6 DEGRADERS | GILEAD SCIENCES INC (US) | 2025-10-16 | — | — | US | disclosed |
| EP-4344702-A2 | PYRAZOLYL DERIVATIVES USEFUL AS ANTI-CANCER AGENTS | Novartis AG (CH) | 2024-04-03 | — | — | EP | disclosed |
| EP-4076662-B1 | PYRAZOLYL DERIVATIVES USEFUL AS ANTI-CANCER AGENTS | NOVARTIS AG (CH) | 2024-01-31 | — | — | EP | disclosed |
| US-11702409-B2 | Pyrazolyl derivatives useful as anti-cancer agents | NOVARTIS AG (CH) | 2023-07-18 | — | — | US | disclosed |
| US-20220363670-A1 | Pyrazolyl derivatives useful as anti-cancer agents | NOVARTIS AG (CH) | 2022-11-17 | — | — | US | disclosed |
| EP-4076662-A1 | PYRAZOLYL DERIVATIVES USEFUL AS ANTI-CANCER AGENTS | Novartis AG (CH) | 2022-10-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11702409-B2 | Pyrazolyl derivatives useful as anti-cancer agents | PAK5, CYP51A1, SF3B5 | TP53 9/4885MAPT 4048/4885NPC1 718/4885 |
| US-20250325677-A1 | STAT6 DEGRADERS | STAT6, STAT5B, STAT1 | TP53 10/4885MAPT 1017/4885NPC1 2139/4885 |
| US-20250320205-A1 | STAT6 DEGRADERS | STAT6, STAT1, STAT5B | TP53 9/4885MAPT 1034/4885NPC1 2380/4885 |
| US-20220363670-A1 | Pyrazolyl derivatives useful as anti-cancer agents | PAK5, CYP51A1, SF3B5 | TP53 9/4885MAPT 4048/4885NPC1 718/4885 |
| US-20250320206-A1 | STAT6 DEGRADERS | STAT6, STAT5B, STAT1 | TP53 10/4885MAPT 1017/4885NPC1 2139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.